Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Läkemedel & Handel |
The Swedish Dental and Pharmaceutical Benefits Agency (TLV) has today decided that Mellozzan (melatonin) tablets 0.5mg, 1mg, 2mg, 3mg, 4mg, 5mg should be included in the pharmaceutical benefit (reimbursement) system with a limitation to the indication "Insomnia in children and adolescents 6 - 17 years with ADHD where sleep hygiene measures have been insufficient".
5-7% of children and young people in Sweden have ADHD according to the National Board of Health and Welfare, and the incidence of children with sleep difficulties (insomnia) is very high, up to 80%, among these. The result is a vicious circle where lack of sleep aggravates ADHD symptoms during the day, which in turn negatively affects sleep at night. Not only the child, but also parents and other family members experience a reduced quality of life due to this, studies show", says Christer Fåhraeus, CEO of EQL Pharma. "Melatonin, which is the active substance in Mellozzan, is also a body-specific hormone and is today classified as the only permitted pharmaceutical for these children. But it is important that they do not take a larger dose than necessary, which is why we offer 6 different strengths. "